Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Research & Development: 2012-2025

Historic Research & Development for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $75.2 million.

  • Iovance Biotherapeutics' Research & Development rose 12.14% to $75.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.5 million, marking a year-over-year increase of 4.10%. This contributed to the annual value of $282.3 million for FY2024, which is 17.94% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Research & Development stood at $75.2 million for Q3 2025, which was down 5.28% from $79.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Research & Development high stood at $87.5 million for Q3 2023, and its period low was $62.1 million during Q2 2024.
  • Its 3-year average for Research & Development is $78.3 million, with a median of $79.4 million in 2025.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Research & Development dropped by 28.10% in 2024, and later climbed by 27.83% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Research & Development (Quarterly) stood at $87.5 million in 2023, then declined by 11.84% to $77.1 million in 2024, then grew by 12.14% to $75.2 million in 2025.
  • Its last three reported values are $75.2 million in Q3 2025, $79.4 million for Q2 2025, and $76.9 million during Q1 2025.